Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
Authors' conclusion
Incidences of VTE and PE were higher with tofacitinib (10 > 5 mg BID) versus TNFi and were generally consistent over time.
Study context
- Population
- Patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor
- Comparison
- Tofacitinib 5 or 10 mg BID vs TNFi
- Primary endpoint
- Cumulative probabilities and incidence rates (patients with first events/100 patient-years) by 6-month intervals of adjudicated VTE, DVT and pulmonary embolism (PE)
Methodological detailsCox regression
- Cox regression
Primary result
As reported in the abstract
Cumulative probabilities for VTE and PE
- Higher with tofacitinib 10 mg BID, but not 5 mg BID, vs TNFi
- Incidence rates consistent across 6-month intervals within treatments
- Post hoc
Further findings
Risk factors for venous thromboembolism (VTE) across treatments
- Prior VTE, BMI ≥35 kg/m², older age and history of chronic lung disease
Disease activity (CDAI) at time of VTE
- Most patients with VTE had active disease by CDAI
Original publication
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients. Arthritis Rheumatol. Published 19 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →